CA2841751A1 - Method for timing a colonoscopy wherein a picosulate composition is administered - Google Patents
Method for timing a colonoscopy wherein a picosulate composition is administered Download PDFInfo
- Publication number
- CA2841751A1 CA2841751A1 CA2841751A CA2841751A CA2841751A1 CA 2841751 A1 CA2841751 A1 CA 2841751A1 CA 2841751 A CA2841751 A CA 2841751A CA 2841751 A CA2841751 A CA 2841751A CA 2841751 A1 CA2841751 A1 CA 2841751A1
- Authority
- CA
- Canada
- Prior art keywords
- bowel
- procedure
- composition
- hours
- colonoscopy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 84
- 238000002052 colonoscopy Methods 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- UJIDKYTZIQTXPM-UHFFFAOYSA-N [4-[pyridin-2-yl-(4-sulfooxyphenyl)methyl]phenyl] hydrogen sulfate Chemical compound C1=CC(OS(=O)(=O)O)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OS(O)(=O)=O)C=C1 UJIDKYTZIQTXPM-UHFFFAOYSA-N 0.000 claims abstract description 27
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 43
- GOZDTZWAMGHLDY-UHFFFAOYSA-L sodium picosulfate Chemical compound [Na+].[Na+].C1=CC(OS(=O)(=O)[O-])=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OS([O-])(=O)=O)C=C1 GOZDTZWAMGHLDY-UHFFFAOYSA-L 0.000 claims description 38
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 13
- 239000000395 magnesium oxide Substances 0.000 claims description 13
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 13
- 229960005077 sodium picosulfate Drugs 0.000 claims description 13
- 230000037406 food intake Effects 0.000 abstract description 3
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 38
- 210000001072 colon Anatomy 0.000 description 33
- 229920001223 polyethylene glycol Polymers 0.000 description 31
- 238000002360 preparation method Methods 0.000 description 31
- 238000011282 treatment Methods 0.000 description 31
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 229960000503 bisacodyl Drugs 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 229960000869 magnesium oxide Drugs 0.000 description 10
- 229960004106 citric acid Drugs 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000001815 ascending colon Anatomy 0.000 description 8
- 206010009944 Colon cancer Diseases 0.000 description 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 210000004877 mucosa Anatomy 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 229960005336 magnesium citrate Drugs 0.000 description 6
- 239000004337 magnesium citrate Substances 0.000 description 6
- 235000002538 magnesium citrate Nutrition 0.000 description 6
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 6
- 239000011521 glass Substances 0.000 description 5
- 229940100688 oral solution Drugs 0.000 description 5
- 229940059097 powder for oral solution Drugs 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 229960004543 anhydrous citric acid Drugs 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 238000001839 endoscopy Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 235000020888 liquid diet Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 2
- 208000037062 Polyps Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical class C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000002565 electrocardiography Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 235000019223 lemon-lime Nutrition 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000002746 orthostatic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940050929 polyethylene glycol 3350 Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- -1 Light 3.5 gm Chemical compound 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920003182 Surlyn® Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000799 cathartic agent Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 238000010878 colorectal surgery Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007950 delayed release tablet Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000008147 saline laxative Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161508189P | 2011-07-15 | 2011-07-15 | |
| US61/508,189 | 2011-07-15 | ||
| PCT/US2012/046874 WO2013012783A1 (en) | 2011-07-15 | 2012-07-16 | Method for timing a colonoscopy wherein a picosulate composition is administered |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2841751A1 true CA2841751A1 (en) | 2013-01-24 |
Family
ID=46642617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2841751A Abandoned CA2841751A1 (en) | 2011-07-15 | 2012-07-16 | Method for timing a colonoscopy wherein a picosulate composition is administered |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9669110B2 (enExample) |
| EP (2) | EP2731607B1 (enExample) |
| JP (2) | JP6376975B2 (enExample) |
| KR (1) | KR20140063602A (enExample) |
| CN (1) | CN103841970A (enExample) |
| AU (1) | AU2012284200B2 (enExample) |
| BR (1) | BR112014000843A8 (enExample) |
| CA (1) | CA2841751A1 (enExample) |
| DK (1) | DK2731607T3 (enExample) |
| ES (1) | ES2655172T3 (enExample) |
| HU (1) | HUE034895T2 (enExample) |
| MX (1) | MX352647B (enExample) |
| NO (1) | NO2731607T3 (enExample) |
| PL (1) | PL2731607T3 (enExample) |
| WO (1) | WO2013012783A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| TWI539959B (zh) | 2008-02-11 | 2016-07-01 | 菲瑞茵國際中心股份有限公司 | 治療轉移階段攝護腺癌的方法 |
| CN105663059A (zh) * | 2009-05-01 | 2016-06-15 | 辉凌公司 | 用于治疗前列腺癌的组合物 |
| US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| DK2632934T3 (en) | 2010-10-27 | 2017-01-23 | Ferring Bv | Process for the preparation of Degarelix and its intermediates |
| EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| SI2854831T1 (sl) | 2012-06-01 | 2024-11-29 | Ferring B.V. | Izdelava degareliksa |
| CN103405395B (zh) * | 2013-08-23 | 2015-04-22 | 山东省医药工业研究所 | 匹可硫酸钠肠溶片及其制备方法 |
| KR101420315B1 (ko) | 2014-03-19 | 2014-07-17 | 남봉길 | 약학적 액제 조성물 |
| CN109310774A (zh) * | 2015-08-17 | 2019-02-05 | 费林股份公司 | 含有匹可硫酸盐和柠檬酸镁的液体制剂 |
| CN105456264B (zh) * | 2015-12-03 | 2018-07-10 | 广州瑞尔医药科技有限公司 | 双效缓泻的药物组合物及其制备方法 |
| TW201804996A (zh) | 2016-07-08 | 2018-02-16 | 輝凌責任有限公司 | 含有匹可硫酸鹽(picosulfate)之安定液體調配物 |
| GB2559405A (en) * | 2017-02-06 | 2018-08-08 | Owlstone Med Ltd | Improvements in or relating to preparation of subjects for medical or veterinary examination |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110076339A1 (en) * | 2008-05-23 | 2011-03-31 | Kingston General Hospital | Colon Cleansing Method and Kit |
| US20140087007A1 (en) | 2012-09-27 | 2014-03-27 | Braintree Laboratories, Inc. | Bowel cleansing preparations |
-
2012
- 2012-07-16 NO NO12745940A patent/NO2731607T3/no unknown
- 2012-07-16 JP JP2014521688A patent/JP6376975B2/ja active Active
- 2012-07-16 KR KR1020147003785A patent/KR20140063602A/ko not_active Ceased
- 2012-07-16 PL PL12745940T patent/PL2731607T3/pl unknown
- 2012-07-16 EP EP12745940.2A patent/EP2731607B1/en active Active
- 2012-07-16 WO PCT/US2012/046874 patent/WO2013012783A1/en not_active Ceased
- 2012-07-16 CA CA2841751A patent/CA2841751A1/en not_active Abandoned
- 2012-07-16 ES ES12745940.2T patent/ES2655172T3/es active Active
- 2012-07-16 EP EP17177814.5A patent/EP3269368A1/en not_active Withdrawn
- 2012-07-16 AU AU2012284200A patent/AU2012284200B2/en active Active
- 2012-07-16 US US13/549,889 patent/US9669110B2/en active Active
- 2012-07-16 HU HUE12745940A patent/HUE034895T2/hu unknown
- 2012-07-16 CN CN201280042345.2A patent/CN103841970A/zh active Pending
- 2012-07-16 DK DK12745940.2T patent/DK2731607T3/en active
- 2012-07-16 BR BR112014000843A patent/BR112014000843A8/pt not_active Application Discontinuation
- 2012-07-16 MX MX2014000593A patent/MX352647B/es active IP Right Grant
-
2016
- 2016-12-09 JP JP2016238984A patent/JP2017061560A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX352647B (es) | 2017-12-04 |
| JP2017061560A (ja) | 2017-03-30 |
| DK2731607T3 (en) | 2018-01-02 |
| MX2014000593A (es) | 2014-07-30 |
| BR112014000843A8 (pt) | 2017-10-10 |
| WO2013012783A1 (en) | 2013-01-24 |
| US20130018223A1 (en) | 2013-01-17 |
| AU2012284200A1 (en) | 2014-02-06 |
| JP2014520884A (ja) | 2014-08-25 |
| KR20140063602A (ko) | 2014-05-27 |
| CN103841970A (zh) | 2014-06-04 |
| HUE034895T2 (hu) | 2018-03-28 |
| EP2731607B1 (en) | 2017-10-11 |
| AU2012284200B2 (en) | 2016-09-22 |
| BR112014000843A2 (pt) | 2017-08-22 |
| EP3269368A1 (en) | 2018-01-17 |
| ES2655172T3 (es) | 2018-02-19 |
| US9669110B2 (en) | 2017-06-06 |
| JP6376975B2 (ja) | 2018-08-22 |
| PL2731607T3 (pl) | 2018-03-30 |
| EP2731607A1 (en) | 2014-05-21 |
| NO2731607T3 (enExample) | 2018-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9669110B2 (en) | Method for timing a colonoscopy | |
| Curran et al. | Oral sodium phosphate solution: a review of its use as a colorectal cleanser | |
| Kastenberg et al. | Efficacy and safety of sodium phosphate tablets compared with PEG solution in colon cleansing: two identically designed, randomized, controlled, parallel group, multicenter phase III trials | |
| US6946149B2 (en) | Salt solution for colon cleansing | |
| Marmo et al. | Effective bowel cleansing before colonoscopy: a randomized study of split-dosage versus non-split dosage regimens of high-volume versus low-volume polyethylene glycol solutions | |
| Katz et al. | A dual-action, low-volume bowel cleanser administered the day before colonoscopy: results from the SEE CLEAR II study | |
| Hookey et al. | Lack of benefit of active preparation compared with a clear fluid–only diet in small-bowel visualization for video capsule endoscopy: results of a randomized, blinded, controlled trial | |
| US20070298008A1 (en) | Method of bowel cleansing | |
| JP6678635B2 (ja) | 大腸内視鏡検査前処置 | |
| Manes et al. | Colon cleansing for colonoscopy in patients with ulcerative colitis: efficacy and acceptability of a 2-L PEG plus bisacodyl versus 4-L PEG | |
| JP2020527580A (ja) | 胃滞留性胆汁酸捕捉剤剤形の有効性 | |
| AU2004320512A1 (en) | Method of bowel cleansing | |
| CA2725125A1 (en) | Colon cleansing method and kit | |
| HK1198006B (en) | Method for timing a colonoscopy wherein a picosulate composition is administered | |
| HK1198006A (en) | Method for timing a colonoscopy wherein a picosulate composition is administered | |
| KR102664492B1 (ko) | 검사 당일 복용량이 감소된 장 세정용 조성물 | |
| US12290529B2 (en) | Methods of administering safe colon cleansing compositions | |
| US20240350426A1 (en) | Bowel cleansing composition with reduced dosage on the day of examination | |
| Cheng et al. | 3 Liter Polyethylene Glycol is Not Inferior to The Standard Bowel Preparation in Chinese Population with Equal Efficacy: A Randomized, Controlled Trial | |
| Katz et al. | A dual-action, low-volume bowel cleanser | |
| Ahmed Abdi | Comparison between two different colon cleansing methods prior to colonoscopy | |
| Wei et al. | Quality of colon cancer pathology reporting: A process of care study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170713 |
|
| FZDE | Discontinued |
Effective date: 20200903 |